Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 81 entries
Sorted by: Best Match Show Resources per page
"Why can't new grads think like nurses?".

Nurse educator

Drogos S.
PMID: 7761021
Nurse Educ. 1995 Jan-Feb;20(1):10.

No abstract available.

Cite
Drogos S. "Why can't new grads think like nurses?". Nurse Educ. 1995;20(1):10
Drogos, S. (1995). "Why can't new grads think like nurses?". Nurse educator, 20(1), 10.
Drogos, S. ""Why can't new grads think like nurses?"." Nurse educator vol. 20,1 (1995): 10.
Drogos S. "Why can't new grads think like nurses?". Nurse Educ. 1995 Jan-Feb;20(1):10. PMID: 7761021.
Copy Download .nbib Format: NLM
Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis.

Pediatric neurology briefs

Nita DA, Hahn CD.
PMID: 27396956
Pediatr Neurol Briefs. 2016 Mar;30(3):18. doi: 10.15844/pedneurbriefs-30-3-1.

Investigators from Nationwide Children's Hospital performed an observational cohort study of early post-traumatic seizures (EPTS) among 34 children with moderate to severe traumatic brain injury (TBI) who received levetiracetam (LEV) prophylaxis following admission to their pediatric intensive care unit.

Cite
Nita DA, Hahn CD. Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis. Pediatr Neurol Briefs. 2016;30(3):18doi: 10.15844/pedneurbriefs-30-3-1.
Nita, D. A., & Hahn, C. D. (2016). Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis. Pediatric neurology briefs, 30(3), 18. https://doi.org/10.15844/pedneurbriefs-30-3-1
Nita, Dragos A, and Hahn, Cecil D. "Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis." Pediatric neurology briefs vol. 30,3 (2016): 18. doi: https://doi.org/10.15844/pedneurbriefs-30-3-1
Nita DA, Hahn CD. Levetiracetam for Pediatric Posttraumatic Seizure Prophylaxis. Pediatr Neurol Briefs. 2016 Mar;30(3):18. doi: 10.15844/pedneurbriefs-30-3-1. PMID: 27396956; PMCID: PMC4936969.
Copy Download .nbib Format: NLM
Doppler-induced unidirectional operation of a continuous-wave Raman ring laser in H2.

Applied optics

Roos PA, Meng LS, Carlsten JL.
PMID: 14526840
Appl Opt. 2003 Sep 20;42(27):5517-21. doi: 10.1364/ao.42.005517.

We demonstrate stable operation of a diode-pumped cw Raman ring laser in diatomic hydrogen gas. Doppler-induced asymmetry between the the forward and the backward Raman gains leads to inherent unidirectional operation in the forward direction without intracavity optical elements....

Cite
Roos PA, Meng LS, Carlsten JL. Doppler-induced unidirectional operation of a continuous-wave Raman ring laser in H2. Appl Opt. 2003;42(27):5517-21doi: 10.1364/ao.42.005517.
Roos, P. A., Meng, L. S., & Carlsten, J. L. (2003). Doppler-induced unidirectional operation of a continuous-wave Raman ring laser in H2. Applied optics, 42(27), 5517-21. https://doi.org/10.1364/ao.42.005517
Roos, Peter A, et al. "Doppler-induced unidirectional operation of a continuous-wave Raman ring laser in H2." Applied optics vol. 42,27 (2003): 5517-21. doi: https://doi.org/10.1364/ao.42.005517
Roos PA, Meng LS, Carlsten JL. Doppler-induced unidirectional operation of a continuous-wave Raman ring laser in H2. Appl Opt. 2003 Sep 20;42(27):5517-21. doi: 10.1364/ao.42.005517. PMID: 14526840.
Copy Download .nbib Format: NLM
Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?.

Journal of clinical medicine

Drosos AA, Pelechas E, Voulgari PV.
PMID: 31426398
J Clin Med. 2019 Aug 16;8(8). doi: 10.3390/jcm8081237.

Despite the significant progress in Rheumatoid Arthritis (RA) therapeutics, there are several reports in the literature claiming that the size of unmet needs in RA is large. In the era before biologics, there was indeed a significant number of...

Cite
Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. J Clin Med. 2019;8(8)doi: 10.3390/jcm8081237.
Drosos, A. A., Pelechas, E., & Voulgari, P. V. (2019). Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. Journal of clinical medicine, 8(8), . https://doi.org/10.3390/jcm8081237
Drosos, Alexandros A, et al. "Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?." Journal of clinical medicine vol. 8,8 (2019). doi: https://doi.org/10.3390/jcm8081237
Drosos AA, Pelechas E, Voulgari PV. Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?. J Clin Med. 2019 Aug 16;8(8). doi: 10.3390/jcm8081237. PMID: 31426398; PMCID: PMC6722985.
Copy Download .nbib Format: NLM
Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke.

Frontiers in neurology

McPherson JG, Ellis MD, Harden RN, Carmona C, Drogos JM, Heckman CJ, Dewald JPA.
PMID: 29977224
Front Neurol. 2018 Jun 21;9:470. doi: 10.3389/fneur.2018.00470. eCollection 2018.

In chronic hemiparetic stroke, increased shoulder abductor activity causes involuntary increases in elbow, wrist, and finger flexor activation, an abnormal muscle coactivation pattern known as the flexion synergy. Recent evidence suggests that flexion synergy expression may reflect recruitment of...

Cite
McPherson JG, Ellis MD, Harden RN, et al. Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke. Front Neurol. 2018;9:470doi: 10.3389/fneur.2018.00470.
McPherson, J. G., Ellis, M. D., Harden, R. N., Carmona, C., Drogos, J. M., Heckman, C. J., & Dewald, J. P. A. (2018). Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke. Frontiers in neurology, 9470. https://doi.org/10.3389/fneur.2018.00470
McPherson, Jacob G, et al. "Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke." Frontiers in neurology vol. 9 (2018): 470. doi: https://doi.org/10.3389/fneur.2018.00470
McPherson JG, Ellis MD, Harden RN, Carmona C, Drogos JM, Heckman CJ, Dewald JPA. Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke. Front Neurol. 2018 Jun 21;9:470. doi: 10.3389/fneur.2018.00470. eCollection 2018. PMID: 29977224; PMCID: PMC6021513.
Copy Download .nbib Format: NLM
Improving Hand Function of Severely Impaired Chronic Hemiparetic Stroke Individuals Using Task-Specific Training With the ReIn-Hand System: A Case Series.

Frontiers in neurology

Camona C, Wilkins KB, Drogos J, Sullivan JE, Dewald JPA, Yao J.
PMID: 30464754
Front Neurol. 2018 Nov 07;9:923. doi: 10.3389/fneur.2018.00923. eCollection 2018.

No abstract available.

Cite
Camona C, Wilkins KB, Drogos J, et al. Improving Hand Function of Severely Impaired Chronic Hemiparetic Stroke Individuals Using Task-Specific Training With the ReIn-Hand System: A Case Series. Front Neurol. 2018;9:923doi: 10.3389/fneur.2018.00923.
Camona, C., Wilkins, K. B., Drogos, J., Sullivan, J. E., Dewald, J. P. A., & Yao, J. (2018). Improving Hand Function of Severely Impaired Chronic Hemiparetic Stroke Individuals Using Task-Specific Training With the ReIn-Hand System: A Case Series. Frontiers in neurology, 9923. https://doi.org/10.3389/fneur.2018.00923
Camona, Carolina, et al. "Improving Hand Function of Severely Impaired Chronic Hemiparetic Stroke Individuals Using Task-Specific Training With the ReIn-Hand System: A Case Series." Frontiers in neurology vol. 9 (2018): 923. doi: https://doi.org/10.3389/fneur.2018.00923
Camona C, Wilkins KB, Drogos J, Sullivan JE, Dewald JPA, Yao J. Improving Hand Function of Severely Impaired Chronic Hemiparetic Stroke Individuals Using Task-Specific Training With the ReIn-Hand System: A Case Series. Front Neurol. 2018 Nov 07;9:923. doi: 10.3389/fneur.2018.00923. eCollection 2018. PMID: 30464754; PMCID: PMC6234834.
Copy Download .nbib Format: NLM
Genetic Risk, Vascular Function, and Subjective Cognitive Complaints Predict Objective Cognitive Function in Healthy Older Adults: Results From the Brain in Motion Study.

Frontiers in integrative neuroscience

Tyndall AV, Longman RS, Sajobi TT, Parboosingh JS, Drogos LL, Davenport MH, Eskes GA, Hogan DB, Hill MD, Poulin MJ.
PMID: 33224030
Front Integr Neurosci. 2020 Nov 03;14:571683. doi: 10.3389/fnint.2020.571683. eCollection 2020.

Aging is associated with subjective memory complaints. Approximately half of those with subjective memory complaints have objective cognitive impairment. Previous studies have provided evidence of an association between genetic risk for Alzheimer's disease (AD) and dementia progression. Also, aging...

Cite
Tyndall AV, Longman RS, Sajobi TT, et al. Genetic Risk, Vascular Function, and Subjective Cognitive Complaints Predict Objective Cognitive Function in Healthy Older Adults: Results From the Brain in Motion Study. Front Integr Neurosci. 2020;14:571683doi: 10.3389/fnint.2020.571683.
Tyndall, A. V., Longman, R. S., Sajobi, T. T., Parboosingh, J. S., Drogos, L. L., Davenport, M. H., Eskes, G. A., Hogan, D. B., Hill, M. D., & Poulin, M. J. (2020). Genetic Risk, Vascular Function, and Subjective Cognitive Complaints Predict Objective Cognitive Function in Healthy Older Adults: Results From the Brain in Motion Study. Frontiers in integrative neuroscience, 14571683. https://doi.org/10.3389/fnint.2020.571683
Tyndall, Amanda V, et al. "Genetic Risk, Vascular Function, and Subjective Cognitive Complaints Predict Objective Cognitive Function in Healthy Older Adults: Results From the Brain in Motion Study." Frontiers in integrative neuroscience vol. 14 (2020): 571683. doi: https://doi.org/10.3389/fnint.2020.571683
Tyndall AV, Longman RS, Sajobi TT, Parboosingh JS, Drogos LL, Davenport MH, Eskes GA, Hogan DB, Hill MD, Poulin MJ. Genetic Risk, Vascular Function, and Subjective Cognitive Complaints Predict Objective Cognitive Function in Healthy Older Adults: Results From the Brain in Motion Study. Front Integr Neurosci. 2020 Nov 03;14:571683. doi: 10.3389/fnint.2020.571683. eCollection 2020. PMID: 33224030; PMCID: PMC7669615.
Copy Download .nbib Format: NLM
Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review.

Current rheumatology reviews

Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA.
PMID: 33213352
Curr Rheumatol Rev. 2021;17(2):267-270. doi: 10.2174/1573397116666201119151349.

BACKGROUND: Psoriasis (Pso) is a common chronic inflammatory disease affecting the skin, both sexes, and all ages. It can be associated with other chronic inflammatory musculoskeletal disorders and certain drugs, including tumor necrosis factor α (TNFα) antagonists.CASE PRESENTATION: A...

Cite
Pelechas E, Papoudou-Bai A, Voulgari PV, et al. Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Curr Rheumatol Rev. 2021;17(2):267-270doi: 10.2174/1573397116666201119151349.
Pelechas, E., Papoudou-Bai, A., Voulgari, P. V., & Drosos, A. A. (2021). Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Current rheumatology reviews, 17(2), 267-270. https://doi.org/10.2174/1573397116666201119151349
Pelechas, Eleftherios, et al. "Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review." Current rheumatology reviews vol. 17,2 (2021): 267-270. doi: https://doi.org/10.2174/1573397116666201119151349
Pelechas E, Papoudou-Bai A, Voulgari PV, Drosos AA. Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review. Curr Rheumatol Rev. 2021;17(2):267-270. doi: 10.2174/1573397116666201119151349. PMID: 33213352.
Copy Download .nbib Format: NLM
Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817).

Mediterranean journal of rheumatology

Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Triantafyllidou E, Tsalavos S, Andrianakos A, Drosos AA.
PMID: 32185362
Mediterr J Rheumatol. 2019 Sep 30;30(3):177-185. doi: 10.31138/mjr.30.3.177. eCollection 2019 Sep.

OBJECTIVE/AIM: One of the most important factors that affect a treatment's performance in rheumatoid arthritis (RA) is adherence to medications. According to literature, there are several reasons for non-adherence in RA patients with some of them being related to...

Cite
Markatseli TE, Theodoridou A, Zakalka M, et al. Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817). Mediterr J Rheumatol. 2019;30(3):177-185doi: 10.31138/mjr.30.3.177.
Markatseli, T. E., Theodoridou, A., Zakalka, M., Koukli, E., Triantafyllidou, E., Tsalavos, S., Andrianakos, A., & Drosos, A. A. (2019). Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817). Mediterranean journal of rheumatology, 30(3), 177-185. https://doi.org/10.31138/mjr.30.3.177
Markatseli, Theodora E, et al. "Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817)." Mediterranean journal of rheumatology vol. 30,3 (2019): 177-185. doi: https://doi.org/10.31138/mjr.30.3.177
Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Triantafyllidou E, Tsalavos S, Andrianakos A, Drosos AA. Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817). Mediterr J Rheumatol. 2019 Sep 30;30(3):177-185. doi: 10.31138/mjr.30.3.177. eCollection 2019 Sep. PMID: 32185362; PMCID: PMC7045860.
Copy Download .nbib Format: NLM
ACL Reconstruction Combined With the Arnold-Coker Modification of the MacIntosh Lateral Extra-articular Tenodesis: Long-term Clinical and Radiological Outcomes.

The American journal of sports medicine

Viglietta E, Ponzo A, Monaco E, Iorio R, Drogo P, Andreozzi V, Conteduca F, Ferretti A.
PMID: 34939890
Am J Sports Med. 2021 Dec 23;3635465211062609. doi: 10.1177/03635465211062609. Epub 2021 Dec 23.

BACKGROUND: Interest in the role of lateral extra-articular tenodesis (LET) in preventing rotatory instability and the pivot-shift phenomenon after anterior cruciate ligament reconstruction (ACLR) has been recently renewed. Nevertheless, there is still concern about overconstraint of the lateral compartment...

Cite
Viglietta E, Ponzo A, Monaco E, et al. ACL Reconstruction Combined With the Arnold-Coker Modification of the MacIntosh Lateral Extra-articular Tenodesis: Long-term Clinical and Radiological Outcomes. Am J Sports Med. 2021;3635465211062609doi: 10.1177/03635465211062609.
Viglietta, E., Ponzo, A., Monaco, E., Iorio, R., Drogo, P., Andreozzi, V., Conteduca, F., & Ferretti, A. (2021). ACL Reconstruction Combined With the Arnold-Coker Modification of the MacIntosh Lateral Extra-articular Tenodesis: Long-term Clinical and Radiological Outcomes. The American journal of sports medicine, 3635465211062609. https://doi.org/10.1177/03635465211062609
Viglietta, Edoardo, et al. "ACL Reconstruction Combined With the Arnold-Coker Modification of the MacIntosh Lateral Extra-articular Tenodesis: Long-term Clinical and Radiological Outcomes." The American journal of sports medicine vol. (2021): 3635465211062609. doi: https://doi.org/10.1177/03635465211062609
Viglietta E, Ponzo A, Monaco E, Iorio R, Drogo P, Andreozzi V, Conteduca F, Ferretti A. ACL Reconstruction Combined With the Arnold-Coker Modification of the MacIntosh Lateral Extra-articular Tenodesis: Long-term Clinical and Radiological Outcomes. Am J Sports Med. 2021 Dec 23;3635465211062609. doi: 10.1177/03635465211062609. Epub 2021 Dec 23. PMID: 34939890.
Copy Download .nbib Format: NLM
Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis.

Therapeutics and clinical risk management

Pelechas E, Voulgari PV, Drosos AA.
PMID: 31564885
Ther Clin Risk Manag. 2019 Sep 04;15:1073-1079. doi: 10.2147/TCRM.S167452. eCollection 2019.

Rheumatoid arthritis (RA) is an autoimmune disease that is characterised by synovial inflammation and progressive joint disorder with significant pain and stiffness, which lead to functional disability and systemic complications if left untreated. Although methotrexate (MTX) is the cornerstone...

Cite
Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:1073-1079doi: 10.2147/TCRM.S167452.
Pelechas, E., Voulgari, P. V., & Drosos, A. A. (2019). Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Therapeutics and clinical risk management, 151073-1079. https://doi.org/10.2147/TCRM.S167452
Pelechas, Eleftherios, et al. "Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis." Therapeutics and clinical risk management vol. 15 (2019): 1073-1079. doi: https://doi.org/10.2147/TCRM.S167452
Pelechas E, Voulgari PV, Drosos AA. Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2019 Sep 04;15:1073-1079. doi: 10.2147/TCRM.S167452. eCollection 2019. PMID: 31564885; PMCID: PMC6732515.
Copy Download .nbib Format: NLM
Dermatomyositis sine myositis - Case presentation.

Mediterranean journal of rheumatology

Kaltsonoudis E, Pelechas E, Drosos AA.
PMID: 32185256
Mediterr J Rheumatol. 2017 Mar 28;28(1):57-58. doi: 10.31138/mjr.28.1.57. eCollection 2017 Mar.

In this case, we present a patient with unilateral salivary gland enlargement and periorbital edema with erythematous rash. We discuss the differential diagnosis and the relevant therapy.

Cite
Kaltsonoudis E, Pelechas E, Drosos AA. Dermatomyositis sine myositis - Case presentation. Mediterr J Rheumatol. 2017;28(1):57-58doi: 10.31138/mjr.28.1.57.
Kaltsonoudis, E., Pelechas, E., & Drosos, A. A. (2017). Dermatomyositis sine myositis - Case presentation. Mediterranean journal of rheumatology, 28(1), 57-58. https://doi.org/10.31138/mjr.28.1.57
Kaltsonoudis, Evripidis, et al. "Dermatomyositis sine myositis - Case presentation." Mediterranean journal of rheumatology vol. 28,1 (2017): 57-58. doi: https://doi.org/10.31138/mjr.28.1.57
Kaltsonoudis E, Pelechas E, Drosos AA. Dermatomyositis sine myositis - Case presentation. Mediterr J Rheumatol. 2017 Mar 28;28(1):57-58. doi: 10.31138/mjr.28.1.57. eCollection 2017 Mar. PMID: 32185256; PMCID: PMC7045927.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 81 entries